提醒成功
搜索
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00043 |
| Application | Flow cytometry, animal model study |
| Aliases | cytotoxic T-lymphocyte?associated antigen 4, cytotoxic T-lymphocyte antigen 4, CD152, CTLA4 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG4 |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human CTLA-4 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors. |
Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody B00043
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:
¥2275
-
咨询
-
收藏

微信/QQ登录


首页